Pharma Capital

Silence Therapeutics boss appointed non-exec chairman of University of Oxford spin-out

Ultromics’ technology has so far been applied to echocardiograms (ECGs) to improve the diagnostic accuracy of coronary artery disease from 80% to greater than 95%
echocardiogram
Ultromics is backed by Oxford Sciences Innovation (OSI)

Ali Mortazavi, the boss of gene silencing specialist, Silence Therapeutics PLC (LON:SLN), has been appointed as the non-executive chairman of artificial intelligence and healthcare firm, Ultromics.

Ultromics, which was spun out of University of Oxford earlier this year, is a platform technology that extracts thousands of data points from a single image.

It then uses machine learning, a form of AI, to determine which data points are specific to a certain disease.

Currently the technology has been applied to echocardiograms (ECGs) to improve the diagnostic accuracy of coronary artery disease from 80% to greater than 95%.

“Artificial intelligence will increasingly begin to play a bigger role in medicine as well as other sectors,” said Mortazavi in a statement this morning.

“Ultromics plans to use the combination of Man plus machine rather than Man vs machine in medical imaging.”

View full SLN profile

Silence Therapeutics plc Timeline

View All

Related Articles

Cattle-herd-(Resized).jpg
If UniBio’s plans come to fruition it won’t be too long before the company orchestrates a major adjustment to the food-chain.

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.